Return to homepagePandemic Pact

SBIR Phase II: COVID-19 Rapid Sensing Using Structural DNA Biosensors

  • Funded by National Science Foundation (NSF)
  • Total publications:2 publications

Grant number: 2127436

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2026
  • Known Financial Commitments (USD)

    $998,507
  • Funder

    National Science Foundation (NSF)
  • Principal Investigator

    Xiaohu Yao
  • Research Location

    United States of America
  • Lead Research Institution

    ATOM BIOWORKS INC
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be the development of a platform technology for creating rapid virus diagnostics that directly recognizes the virus surface protein pattern from a patient sample and generates accurate results within minutes. Current standards for high-fidelity viral pathogen diagnostics require complex instruments, technical expertise to run the instruments, and hours to produce and interpret results. The proposed platform creates a virus-specific biosensor that selectively binds to the target virus and produces visible results without time-consuming pre-processing or expensive instruments. Lower cost tests and faster sample-to-result turnovers could result in more effective control of disease spread. This project seeks to develop a highly functional, sensitive, and specific diagnostic for the detection of coronavirus. This technology is based on the company's Pattern-Recognition Enhanced Sensing and Therapeutics (PEST) concept. The solution is a first-in-class diagnostics that uses algorithmically-designed structural DNA to form a trap that may detect and selectively bind a signature pattern of the pathogen. This recognition and binding may generate visual signals without the need of DNA/RNA preprocessing or amplification associated with the current generation of molecular tests (polymerase chain reactions, PCRs). This project will involve building a preclinical prototype of PEST-enabled lateral flow based COVID-19 rapid diagnostics with a goal of providing results for each sample within 5 minutes. This fast test result will be followed by preclinical validation to determine the test's specificity, limits of detection, and implement mechanism to improve the assay specificity and to avoid cross-reaction to other virus types. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

2 Publications linked via Europe PMC

DNA Origami-Templated Aptamer Chiral Structures Realize Cellular Enantioselectivity.

Engineering Novel DNA Nanoarchitectures for Targeted Drug Delivery and Aptamer mediated Apoptosis in Cancer Therapeutics.